We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

AGILENT

Agilent provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling... read more Featured Products: More products

Download Mobile App




Agilent Technologies Expands Portfolio with Acquisition of BioTek Instruments

By LabMedica International staff writers
Posted on 17 Jul 2019
Print article
Agilent Technologies Inc. (Santa Clara, CA, USA), a global leader in the life sciences, diagnostics and applied chemical markets, has signed a definitive agreement to acquire privately-owned BioTek Instruments (Winooski, VT, USA) which designs, manufactures, and distributes innovative life science instrumentation. The acquisition of BioTek makes Agilent well positioned in the large and growing immuno-oncology and immunotherapy markets and expands the company’s presence in biopharma, academia and research. The combination will support novel workflows that reveal more comprehensive insights for live cell analysis.

BioTek is a global leader in the design, manufacture and distribution of innovative life science instrumentation. Its comprehensive product line includes cell imaging systems, microplate readers, washers, dispensers, automated incubators and stackers. These products enable life science research by providing customers with high performance, cost-effective analysis across diverse applications.

Agilent’s acquisition of BioTek accelerates its multi-year growth strategy to expand its position in cell analysis, a fast-growing multi-billion dollar market. Agilent entered the cell analysis segment in 2015 with the acquisition of Seahorse Bioscience, a provider of specialized instruments and live-cell, kinetic assays. In January 2018, Agilent broadened its portfolio of cell analysis solutions through the acquisition of Luxcel Biosciences, and in September 2018, it went on to acquire ACEA Biosciences, a pioneer in the development and commercialization of high- performance cell analysis platforms for life science research. With Agilent’s latest acquisition of BioTek, their combined portfolio will enable it to provide a more complete and integrated solution for customers in the important and fast-growing area of live cell analysis.

“BioTek represents a strong strategic fit with Agilent,” said Mike McMullen, Agilent president and CEO. “The combination of these two companies will accelerate our multi-year growth strategy to expand our position in cell analysis. This is another example of Agilent investing in high-growth segments of the life sciences market to serve new and existing customers. Agilent is committed to continuing operations in Vermont and retaining the great team of nearly 500 employees that have been at the core of BioTek’s 50-year history of excellence and success.”

“By combining BioTek’s offerings with Agilent’s, we will deliver a breadth of differentiated workflows, enabling customers to obtain deeper, more reliable insights across a variety of cell analysis applications,” said Jacob Thaysen, president of Agilent’s Life Sciences and Applied Markets Group. “This positions Agilent well in the large and growing immuno-oncology and immunotherapy markets and expands our presence in biopharma, academia and research as customers seek to understand complex cellular environments and interactions.”

“BioTek and Agilent have already been in partnership for over a year, successfully unlocking significant value through joint development of customer solutions,” said Briar Alpert, CEO of BioTek. “Both companies share the same focus on customers and employees, as well as a similar purpose, mission and values. I am confident that this is the winning formula for our employees and customers around the world.”

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Pathology

view channel
Image: The photoacoustic spectral response sensing instrument is based on low-cost laser diodes (Photo courtesy of Khan et al., doi 10.1117/1.JBO.29.1.017002)

Compact Photoacoustic Sensing Instrument Enhances Biomedical Tissue Diagnosis

The pursuit of precise and efficient diagnostic methods is a top priority in the constantly evolving field of biomedical sciences. A promising development in this area is the photoacoustic (PA) technique.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.